Administration of slowly released recombinant interleukin 2 Augmentation of the efficacy of adoptive immunotherapy with lymphokine-activated killer (LAK) cells
- 1 July 1986
- journal article
- research article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 91 (1), 21-27
- https://doi.org/10.1016/0022-1759(86)90097-9
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2Cancer Immunology, Immunotherapy, 1986
- Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2.The Journal of Immunology, 1985
- Use of millipore diffusion chambers to assay in vivo IL-2 activityJournal of Immunological Methods, 1985
- Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo.The Journal of Immunology, 1984
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.The Journal of Experimental Medicine, 1982
- Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo.The Journal of Experimental Medicine, 1981
- Cloned lines of natural killer cellsNature, 1980
- T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu miceNature, 1980
- Long term culture of tumour-specific cytotoxic T cellsNature, 1977